To the Editor:Multiple myeloma (MM), a malignancy of mature plasma cells, is considered the second most common hematological malignancy in the United States [1]. While recent advances in therapeutic options have significantly prolonged progression-free and overall survival, MM remains an incurable disease [2].

致编辑：多发性骨髓瘤（MM）是一种成熟浆细胞的恶性肿瘤，被认为是美国第二常见的血液系统恶性肿瘤。虽然治疗选择的最新进展显着延长了无进展生存期和总生存期，但MM仍然是一种无法治愈的疾病（2）。

With increasing efficacy of treatments and advancements in technology, the concept of minimal residual disease (MRD) monitoring for MM was introduced in the early 2010s, to describe the presence of disease detectable below the level of microscopy and routine assays performed on the bone marrow and/or blood specimens.

随着治疗效果的提高和技术的进步，在2010年代早期引入了MM最小残留病（MRD）监测的概念，以描述在显微镜和常规检测水平以下可检测到的疾病的存在。骨髓和/或血液标本。

Two types of assays became widely accepted for evaluating the presence of residual abnormal plasma cells: DNA-based next-generation sequencing (NGS) assays and high sensitivity flow cytometry (FC) immunophenotyping assays. In 2016, the International Myeloma Working Group (IMWG) published guidelines for MRD testing in MM with the intent to use the term “MRD” for assays with the minimum sensitivity of 10−5 [3].

两种类型的检测方法被广泛用于评估残留异常浆细胞的存在：基于DNA的下一代测序（NGS）检测和高灵敏度流式细胞术（FC）免疫分型检测。2016年，国际骨髓瘤工作组（IMWG）发布了MM MRD检测指南，旨在使用术语“MRD”进行最低灵敏度为10-5的检测。

Currently the only FDA approved test for MM MRD is NGS-based clonoSEQ© by Adaptive Biotechnologies, with the sensitivity of 10−6 [4, 5]. The most widely used FC method has been developed by the Euroflow consortium, composed by 19 laboratories around the world (often referred to as next-generation flow, NGF); this is a 2-tube, 8-color Conformité Européenne in-vitro diagnostic (CE-IVD) assay with the advertised sensitivity of 10−5 [6, 7].

目前，FDA批准的唯一MM MRD测试是自适应生物技术公司的基于NGS的clonoSEQ©测试，灵敏度为10-6[4，5]。使用最广泛的FC方法是由Euroflow consortium开发的，该联盟由世界各地的19个实验室组成（通常称为下一代流量，NGF）；这是一种双管，8色ConformitéEuropéenne体外诊断（CE-IVD）测定法，其灵敏度为10-5[6，7]。

A dry version of the antibody combination panel and the Infinicyt software for analysis and commercialized by Cytognos.Comparison between NGF and NGS methods have been made in the past [8, 9], and in general both methods are considered adequate for MRD assessment at the current definition of 10−5 sensitivity [10]..

抗体组合面板和Infinicyt软件的干燥版本，用于分析并由Cytognos商业化。过去已经对NGF和NGS方法进行了比较[8，9]，通常认为这两种方法都足以在当前10-5灵敏度的定义下进行MRD评估[10]。。

ReferencesSiegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer J Clinicians. 2022;72:7–33.

参考Siegel RL，Miller KD，Fuchs HE，Jemal A.癌症统计，2022年。CA：癌症J临床医生。2022年；72:7-33。

Google Scholar

谷歌学者

Nandakumar B, Kapoor P, Binder M, Buadi FK, Lacy MQ, Gertz MA, et al. Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood. 2020;136:30–1.Article

Nandakumar B，Kapoor P，Binder M，Buadi FK，Lacy MQ，Gertz MA等。新诊断多发性骨髓瘤（MM）患者生存率的持续改善。血。2020年；136:30–1.文章

Google Scholar

谷歌学者

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:E328–46.Article

Kumar S，Paiva B，Anderson KC，Durie B，Landgren O，Moreau P等。国际骨髓瘤工作组关于多发性骨髓瘤反应和最小残留病评估的共识标准。柳叶刀Oncol。2016年；17： E328–46.文章

PubMed

PubMed

Google Scholar

谷歌学者

ClonoSEQ Cleared for Residual Cancer Testing. Cancer Discov. 2018;8:Of6. https://aacrjournals.org/cancerdiscovery/article/8/12/OF6/191941/ClonoSEQ-Cleared-for-Residual-CancerChing T, Duncan ME, Newman-Eerkes T, McWhorter MME, Tracy JM, Steen MS, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.

ClonoSEQ被允许进行残留癌症检测。癌症发现。2018年；8： Of6。https://aacrjournals.org/cancerdiscovery/article/8/12/OF6/191941/ClonoSEQ-Cleared-for-Residual-CancerChingT，Duncan ME，Newman-Eerkes T，McWhorter MME，Tracy JM，Steen MS等。用于建立急性淋巴细胞白血病，慢性淋巴细胞白血病和多发性骨髓瘤中可测量（最小）残留疾病的clonoSEQ测定的分析评估。

BMC Cancer. 2020;20:612.Article .

BMC癌症。2020年；20： 第612条。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.Article

Flores-Montero J，Sanoja-Flores L，Paiva B，Puig N，Garcia-Sanchez O，Bottcher S等。用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的下一代流程。白血病。2017年；

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

van Dongen JJM, Lhermitte L, Bottcher S, Almeida J, van der Velden VHJ, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–75.Article

van Dongen JJM，Lhermitte L，Bottcher S，Almeida J，van der Velden VHJ，Flores Montero J等。用于正常，反应性和恶性白细胞标准化n维流式细胞术免疫分型的EuroFlow抗体组。白血病。2012年；26:1908–75.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10:108.Article

Medina A，Puig N，Flores Montero J，Jimenez C，Sarasquete ME，Garcia Alvarez M等。下一代测序（NGS）和下一代流量（NGF）在多发性骨髓瘤最小残留病（MRD）评估中的比较。血癌J.2020；10： 第108条

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Urushihara R, Takezako N, Yoroidaka T, Yamashita T, Murata R, Satou K, et al. Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. EJHaem.

Urushihara R，Takezako N，Yoroidaka T，Yamashita T，Murata R，Satou K等。八色多参数流式细胞术（EuroFlow NGF）在检测多发性骨髓瘤患者自体移植物中最小/可测量残留疾病方面与下一代测序一样敏感。埃贾姆。

2023;4:184–91.Article .

2023年；4： 184-91条。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988–99.Article

Munshi NC，Avet Loiseau H，Anderson KC，Neri P，Paiva B，Samur M等。一项大型荟萃分析确定了MRD阴性在多发性骨髓瘤患者长期生存结局中的作用。血液Adv.2020；4： 5988-99.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, et al. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 2018;103:1229–34.Article

Sidiqi MH，Aljama MA，Jevremovic D，Morice WG，Timm M，Buadi FK等。浆细胞增殖指数预测干细胞移植治疗的免疫球蛋白轻链淀粉样变性的结果。血液学。2018年；103:1229–34.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Panakkal V, Lakshman A, Shi M, Olteanu H, Horna P, Timm MM, et al. Utility of flow cytometry screening before MRD testing in multiple myeloma. Blood Cancer J. 2023;13:55.Article

Panakkal V，Lakshman A，Shi M，Olteanu H，Horna P，Timm MM等。多发性骨髓瘤MRD检测前流式细胞术筛查的实用性。血癌J.2023；13： 55、条款

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsDivision of Hematopathology, Mayo Clinic, Rochester, MN, USADragan Jevremovic, Min Shi, Pedro Horna, Gregory E. Otteson, Michael M. Timm, Linda B. Baughn, Patricia T. Greipp & Horatiu OlteanuDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USALinda B.

下载参考文献作者信息作者和附属机构明尼苏达州罗切斯特梅奥诊所血液病理学系，USADragan Jevremovic，Min Shi，Pedro Horna，Gregory E.Otteson，Michael M.Timm，Linda B.Baughn，Patricia T.Greipp＆Horatiu OlteanuDivision实验室遗传学和基因组学，实验医学和病理学系，梅奥诊所，明尼苏达州罗切斯特，USALDA B。

Baughn & Patricia T. GreippDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAWilson I. Gonsalves, Prashant Kapoor, Morie A. Gertz, Moritz Binder, Francis K. Buadi, Angela Dispenzieri, Taxiarchis Kourelis, Eli Muchtar, S. Vincent Rajkumar & Shaji K. KumarDepartment of Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, AZ, USAJiehao ZhouAuthorsDragan JevremovicView author publicationsYou can also search for this author in.

鲍恩（Baughn）和帕特丽夏（PatriciaT.Greippid）明尼苏达州罗切斯特梅奥诊所医学系血液学系，USAWilson I.Gonsalves，Prashant Kapoor，Morie A.Gertz，Moritz Binder，FrancisK.Buadi，Angela Dispenzieri，Taxarchis Kourelis，Eli Muchtar，S。Vincent Rajkumar＆Shaji K.KumarDepartment of Laboratory Medicine and Pathology，Mayo Clinic Scottsdale，Scottsdale，AZ，USAJiehao Zhou作者Dragan JevremovicView作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarMin ShiView author publicationsYou can also search for this author in

PubMed谷歌学术评论作者出版物您也可以在

PubMed Google ScholarPedro HornaView author publicationsYou can also search for this author in

PubMed Google ScholarGregory E. OttesonView author publicationsYou can also search for this author in

PubMed Google ScholarGregory E.OttesonView作者出版物您也可以在

PubMed Google ScholarMichael M. TimmView author publicationsYou can also search for this author in

PubMed Google Scholarmamichael M.TimmView作者出版物您也可以在

PubMed Google ScholarLinda B. BaughnView author publicationsYou can also search for this author in

PubMed Google ScholarLinda B.BaughnView作者出版物您也可以在

PubMed Google ScholarPatricia T. GreippView author publicationsYou can also search for this author in

PubMed Google ScholarPatricia T.GreippView作者出版物您也可以在

PubMed Google ScholarWilson I. GonsalvesView author publicationsYou can also search for this author in

PubMed Google ScholarWilson I.GonsalvesView作者出版物您也可以在

PubMed Google ScholarPrashant KapoorView author publicationsYou can also search for this author in

PubMed Google ScholarPrashant KapoorView作者出版物您也可以在

PubMed Google ScholarMorie A. GertzView author publicationsYou can also search for this author in

PubMed Google Scholarmarie A.GertzView作者出版物您也可以在

PubMed Google ScholarMoritz BinderView author publicationsYou can also search for this author in

PubMed Google Scholarmaritz BinderView作者出版物您也可以在

PubMed Google ScholarFrancis K. BuadiView author publicationsYou can also search for this author in

PubMed谷歌学者Francis K.BuadiView作者出版物您也可以在

PubMed Google ScholarJiehao ZhouView author publicationsYou can also search for this author in

PubMed谷歌学者周杰浩查看作者出版物您也可以在

PubMed Google ScholarAngela DispenzieriView author publicationsYou can also search for this author in

PubMed Google ScholarAngela DispenzieriView作者出版物您也可以在

PubMed Google ScholarTaxiarchis KourelisView author publicationsYou can also search for this author in

PubMed Google ScholarTaxiarchis KourelisView作者出版物您也可以在

PubMed Google ScholarEli MuchtarView author publicationsYou can also search for this author in

PubMed Google ScholarEli MuchtarView作者出版物您也可以在

PubMed Google ScholarS. Vincent RajkumarView author publicationsYou can also search for this author in

PubMed谷歌学者。Vincent RajkumarView作者出版物您也可以在

PubMed Google ScholarShaji K. KumarView author publicationsYou can also search for this author in

PubMed Google ScholarShaji K.KumarView作者出版物您也可以在

PubMed Google ScholarHoratiu OlteanuView author publicationsYou can also search for this author in

PubMed Google ScholarHoratiu OlteanuView作者出版物您也可以在

PubMed Google ScholarContributionsDJ, SKK, and HO designed the study; DJ and GEO analyzed the data; DJ wrote the draft of the letter; MS, PH, GEO, MMT, LBB, PTG, WIG, PK, MAG, MB, FKB, JZ, AD, TK, EM, SVM, SKK, and HO critically reviewed the data and the letter.Corresponding authorCorrespondence to.

PubMed谷歌学术贡献SDJ，SKK和HO设计了这项研究；DJ和GEO分析了数据；DJ写了信的草稿；MS，PH，GEO，MMT，LBB，PTG，WIG，PK，MAG，MB，FKB，JZ，AD，TK，EM，SVM，SKK和HO严格审查了数据和信件。对应作者对应。

Dragan Jevremovic.Ethics declarations

德拉根·耶夫雷莫维奇。道德宣言

Competing interests

相互竞争的利益

The authors declare no competing interests.

作者声明没有利益冲突。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissions

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。权限和权限

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material.

开放获取本文是根据知识共享署名非商业性NoDerivatives 4.0国际许可证授权的，该许可证允许以任何媒介或格式进行任何非商业性使用，共享，分发和复制，只要您对原始作者和来源给予适当的信任，提供知识共享许可证的链接，并指出您是否修改了许可材料。

You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

根据本许可证，您无权共享源自本文或其部分的改编材料。本文中的图像或其他第三方材料包含在文章的知识共享许可证中，除非该材料的信用额度中另有说明。如果材料未包含在文章的知识共享许可中，并且您的预期用途不受法律法规的许可或超出许可用途，则您需要直接获得版权所有者的许可。

To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/..

要查看此许可证的副本，请访问http://creativecommons.org/licenses/by-nc-nd/4.0/..

Reprints and permissionsAbout this articleCite this articleJevremovic, D., Shi, M., Horna, P. et al. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms.

转载和许可本文引用本文Jevremovic，D.，Shi，M.，Horna，P。等人。流式细胞术对浆细胞肿瘤最小残留疾病评估的现实敏感性。

Blood Cancer J. 14, 126 (2024). https://doi.org/10.1038/s41408-024-01113-8Download citationReceived: 13 May 2024Revised: 22 July 2024Accepted: 25 July 2024Published: 31 July 2024DOI: https://doi.org/10.1038/s41408-024-01113-8Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

血癌J.14126（2024）。https://doi.org/10.1038/s41408-024-01113-8Download收到引文日期：2024年5月13日修订日期：2024年7月22日接受日期：2024年7月25日发布日期：2024年7月31日OI：https://doi.org/10.1038/s41408-024-01113-8Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供